Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Target Raised at Citizens Jmp

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price increased by stock analysts at Citizens Jmp from $8.00 to $12.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp‘s target price would suggest a potential upside of 50.68% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Citigroup restated an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. Wells Fargo & Company upped their price objective on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, September 30th. HC Wainwright raised their price objective on shares of Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Tuesday, September 29th. Finally, UBS Group boosted their target price on shares of Iovance Biotherapeutics from $7.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.70.

Iovance Biotherapeutics Stock Up 2.9%

NASDAQ:IOVA traded up $0.22 on Friday, hitting $7.96. The stock had a trading volume of 1,767,961 shares, compared to its average volume of 15,777,470. Iovance Biotherapeutics has a 52 week low of $2.08 and a 52 week high of $15.37. The business’s fifty day moving average is $11.38 and its 200 day moving average is $5.94. The company has a market cap of $3.61 billion, a PE ratio of -10.77 and a beta of 0.88.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The company had revenue of $121.47 million for the quarter, compared to analyst estimates of $115.98 million. The firm’s revenue was up 64.8% compared to the same quarter last year. Equities analysts predict that Iovance Biotherapeutics will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Iovance Biotherapeutics

Hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Iovance Biotherapeutics in the second quarter valued at approximately $153,744,000. Palo Alto Investors LP purchased a new stake in shares of Iovance Biotherapeutics during the second quarter valued at approximately $22,032,229. Bank of America Corp DE bought a new stake in Iovance Biotherapeutics during the second quarter worth $20,773,000. Knott David M Jr bought a new stake in Iovance Biotherapeutics during the first quarter worth $5,616,000. Finally, Rice Hall James & Associates LLC purchased a new position in Iovance Biotherapeutics in the second quarter worth $6,406,000. Institutional investors own 77.03% of the company’s stock.

Trending Headlines about Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q3 results topped expectations. Iovance reported about $122 million in revenue, a record, and a loss of $0.05 per share versus the $0.09 loss analysts expected. Amtagvi sales drove growth, gross margin rose to about 60%, and lower R&D costs helped improve results. The company reaffirmed its 2026 revenue outlook. Article: IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
• Positive Sentiment: Sarcoma program gained regulatory momentum. Lifileucel received FDA Fast Track designation following strong sarcoma trial data. Iovance also reported a 55.6% response rate in UPS and DDLPS, with a registrational trial underway. Article: Iovance Biotherapeutics Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
• Neutral Sentiment: An analyst upgraded the stock to Buy after resetting expectations, citing momentum in the Amtagvi melanoma launch. The analyst also cautioned that the opportunity in lung cancer may have been overestimated. Article: Iovance: Reset Expectations Make The Stock a Buy Again
• Negative Sentiment: Lung-cancer data remain a risk. Lifileucel showed a 24.6% response rate across 69 evaluable non-squamous NSCLC patients, slightly below an earlier interim result. The reported 59.1% response rate in a biomarker-selected subgroup is more encouraging, but the treatment’s broader potential remains uncertain. Article: Iovance Reports Q3 2026 Results and Updates

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.